Clinical features of drug-induced liver injury and related risk factors

Lin YunXia; He XiaoBin

doi:10.3969/j.issn.1001-5256.2018.06.021

Issue 6

Jun. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(6): 1237-1241

PDF( 1551 KB)

Clinical features of drug-induced liver injury and related risk factors

DOI: 10.3969/j.issn.1001-5256.2018.06.021

Clinical Medical College, Southwest Medical University

Received Date: 2018-02-28
Published Date: 2018-06-20

Abstract

Abstract

Objective To investigate the clinical features of drug-induced liver injury (DILI) and related risk factors. Methods A retrospective analysis was performed for the clinical data of 208 patients who were diagnosed with DILI in The Affiliated Hospital of Southwest Medical University from January 2013 to November 2017, including the type of drugs, clinical data, and laboratory examination results, and among these patients, 80 with DILI caused by antitubercular agents, antitumor drugs, and immune agents were enrolled as observation group. A total of 80 patients who used these three types of drugs and did not develop DILI were enrolled as control group. Related risk factors were analyzed. An analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups. The chi-square test was used for unordered variables of categorical data, the Mann-Whitney U test was used for ranked data, and a logistic regression analysis was used to identify risk factors. Results Of all patients with DILI, 30. 8% had DILI caused by traditional Chinese medicine. There were significant differences in sex, alanine aminotransferase, aspartate aminotransferase (AST) , total bilirubin (TBil) , gamma-glutamyl transpeptidase (GGT) , and total bile acid (TBA) between patients with different types of DILI (χ2= 6. 081, H = 54. 349, 45. 993, 78. 902, 49. 940, and 21. 934, all P < 0. 05) . There were significant differences in AST, TBil, GGT, and TBA between the patients with different prognoses (H = 1. 728, 6. 322, 6. 440, and 2. 353, all P < 0. 05) . Smoking (odds ratio [OR]= 2. 856, P = 0. 026) , diabetes (OR = 2. 726, P = 0. 042) , hyperlipidemia (OR = 3. 390, P = 0. 003) , and body mass index (BMI) ≥28 kg/m2 (OR = 3. 142, P =0. 009) were risk factors for DILI. Conclusion Most DILI cases are caused by traditional Chinese medicine, and hepatocellular type is the most common type of liver injury. Smoking, diabetes, hyperlipidemia, and BMI ≥28 kg/m2 are risk factors for DILI.
- drug-induced liver injury,
- clinical features,
- risk factors

FullText(HTML)

References(18)

References

[1]WANG G, LIN Y, HOU XF, et al.Discussion on influence factors, mechanism and traditional Chinese medicine pathogenesis of idiosyncratic drug-induced liver injury[J].China J Chin Mater Med, 2017, 42 (16) :3036-3043.

[2]DALAL K, HOLDBROOK T, PEIKI S.Ayurvedic drug induced liver injury[J].World J Hepatol, 2017, 9 (31) :1205-1209.

[3]HU Q, LIU W, SHAO H.Research progress of pharmacotherapy drug-induced liver injury[J].Chin J Clin Pharmacol Ther, 2016, 21 (2) :231-236. (in Chinese) 胡琴, 刘维, 邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学, 2016, 21 (2) :231-236.

[4]REGEV A.How to avoid being surprised by hepatotoxicity at the final stages of drug develo-pment and approval[J].Clin Liver Dis, 2013, 17 (4) :749-767.

[5]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[6]CHALASANI P, HAYASH H, BONKOVSKY L, et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.

[7]GIORDANO C, RIVAS J, ZERVOS X.An update on treatment of drug-induced liver injury[J].Clin Transl Hepatol, 2014, 2 (2) :74-79.

[8]LI L, JIANG W.Clinical analysis of 275 cases of acute drug-induced liver disease[J].Front Med China, 2007, 1 (1) :58-61.

[9]HALLER C, DYER J, KO R, et al.Making a diagnosis of herbal-related toxic hepatitis[J].West J Med, 2002, 176 (1) :39-44.

[10]GOODMAN Z.Phenotypes and pathology of drug-induced liver disease[J].Clin Liver Dis, 2017, 21 (1) :89-101.

[11]SHAO C, WU C, LI J, et al.Clinical characteristics analysis of122 patients with drug induced liver injury[J].Chin Hepatol, 2012, 17 (9) :451-453.

[12]JI CH, ZHANG ZQ, WANG XY, et al.Clinical features of elderly patients with drug-induced liver injury[J].J Clin Hepatol, 2017, 33 (3) :502-506. (in Chinese) 姬琛华, 张竹青, 王晓媛, 等.老年药物性肝损伤患者临床特征分析[J].临床肝胆病杂志, 2017, 33 (3) :502-506.

[13]CHALASANI N, BONKOVSKY H, FONTANA R, et al.Features and outcomes of 899 pat-ients with drug-induced liver injury:the DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352.

[14]LEE W.Drug-induced hepatotoxicity[J].N Engl J Med, 1995, 333 (17) :1118-1127.

[15]LIU LN, ZHAO JX, CHEN WT.et al.Prognostic factors in 138patients with drug-induced liver injury[J].J Pract Hepatol, 2015, 18 (2) :160-163. (in Chinese) 刘丽娜, 赵建学, 陆玮婷, 等.138例药物性肝损伤患者影响预后的因素分析[J].实用肝脏病杂志, 2015, 18 (2) :160-163.

[16]SCHROEDER MJ, HOFFMAN AC.Electronic cigarettes and nicotine clinical pharmacology[J].Tobacco Control, 2014, 23 (Suppl2) :ii30-ii35.

[17]XU LH, ZHANG L, CHEN W, et al.Clinical features and the prognosis of acute drug-induced liver injury[J].J Pract Med, 2013, 29 (3) :3668-3671. (in Chinese) 徐丽红, 张蕾, 陈卫刚, 等.急性药物性肝损伤临床特点及预后分析[J].实用医学杂志, 2013, 29 (3) :3668-3671.

[18]LATIEF M, DAR W, SOFI N, et al.Novel risk factors and early detection of anti tubercular treatment induced liver injury-looking beyond American Thoracic Society Guidelines[J].Indian J Tuberc, 2017, 64 (1) :26-32.

Relative Articles

[1]	Fengxin CHEN, Zhan ZENG, Fangfang SUN, Leiping HU, Yao LU, Lu ZHANG, Minghui LI, XIE Yao. Clinical features and autoantibody characteristics of patients with drug-induced liver injury: An analysis of 419 cases[J]. Journal of Clinical Hepatology, 2022, 38(1): 148-153. doi: 10.3969/j.issn.1001-5256.2022.01.023
[2]	Deliang HUANG, Wei DAI, Jun CHEN, Xiaoguang YE. Clinical features of liver injury induced by anti-tuberculosis drugs and related risk factors[J]. Journal of Clinical Hepatology, 2021, 37(10): 2369-2375. doi: 10.3969/j.issn.1001-5256.2021.10.022
[3]	Jing Jing, He TingTing, Wang RuiLin, Zhang Fan, Niu Ming, Guo YuMing, Zhu Yun, Xiao XiaoHe, Wang JiaBo. Detection of the risk signals of drug-induced liver injury: Challenges and advances[J]. Journal of Clinical Hepatology, 2020, 36(3): 491-496. doi: 10.3969/j.issn.1001-5256.2020.03.002
[4]	Ye LiHong, Wang ChongKui, Shao Chen, Zhang HaiCong, Liu ZhiQuan, Wang TaiLing. Clinical and biochemical features of bile duct injury type of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2020.05.022
[5]	Yang Xue, Tu RongFang, Yang JinHui. Research advances in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 509-513. doi: 10.3969/j.issn.1001-5256.2020.03.006
[6]	Zhang Dan, Feng GuoHe. Current research status of nosocomial infection in patients with severe liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 213-216. doi: 10.3969/j.issn.1001-5256.2019.01.047
[7]	Yu LeCheng, Lai RongTao, Chen ChengWei. Key points and interpretation of EASL clinical practice guidelines: Drug-induced liver injury (2019)[J]. Journal of Clinical Hepatology, 2019, 35(6): 1242-1250. doi: 10.3969/j.issn.1001-5256.2019.06.013
[8]	Zhang YanFang, Guo YuMing, Niu Ming, Ge FeiLin, Jing Jing, Zhu Yun, Zhu ShiShu, Han ZiXin, Wang JiaBo, Liu ShiJing, Xiao XiaoHe. Drug-induced liver injury in children:An analysis of medication and clinical features[J]. Journal of Clinical Hepatology, 2019, 35(3): 579-584. doi: 10.3969/j.issn.1001-5256.2019.03.025
[9]	Zhang YanMei, Sun WenJing, Wen LiangZhi, Liu KaiJun, Wang Bin, Liu Hui, Chen DongFeng, Fu Xin. Clinical features of patients with drug-induced liver injury in China in the last five years[J]. Journal of Clinical Hepatology, 2018, 34(3): 562-566. doi: 10.3969/j.issn.1001-5256.2018.03.023
[10]	Jiang HongLi, Qi YaBin, Zhang Rui, Hu YuLin. Detection rates of autoantibodies in patients with drug-induced liver injury and their clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(1): 164-167. doi: 10.3969/j.issn.1001-5256.2018.01.034
[11]	Zhu ChunWu, Wang HaiNan, Yuan JiLi, Peng Yuan, Zhang YaLei, Xue DongYing, Zhang Qin, Liu ChengHai. Clinical features of drug-induced liver injury: an analysis of 445 cases[J]. Journal of Clinical Hepatology, 2018, 34(2): 354-358. doi: 10.3969/j.issn.1001-5256.2018.02.027
[12]	Yan Rong, Song ZhengJun. Clinical features and prognosis of drug-induced liver injury: An analysis of 95 cases[J]. Journal of Clinical Hepatology, 2018, 34(6): 1242-1247. doi: 10.3969/j.issn.1001-5256.2018.06.022
[13]	Xu CengLi, Gao Min, Guo ChunXia, Xing MinDan, Li Jia. Clinical features of different types of drug-induced liver injury and their association with liver histological changes[J]. Journal of Clinical Hepatology, 2017, 33(5): 924-927. doi: 10.3969/j.issn.1001-5256.2017.05.027
[14]	Ji ChenHua, Zhang ZhuQing, Wang XiaoYuan, Lu ShuMing. Clinical features of elderly patients with drug-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(3): 502-506. doi: 10.3969/j.issn.1001-5256.2017.03.021
[15]	Yang JunYang, Qi TangKai, Zhang RenFang, Liu Li, Shen YinZhong, Ji YongJia, Lu HongZhou. Clinical features and prognosis of AIDS complicated by drug-induced liver injury: an analysis of 119 cases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1537-1542. doi: 10.3969/j.issn.1001-5256.2017.08.026
[16]	Xiao ErHui, Ning HuiBin, Kang Yi, Cao YongGe, Wei JunFeng, Shang Jia. Clinical features and risk factors for patients with liver failure complicated by invasive pulmonary aspergillosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1378-1381. doi: 10.3969/j.issn.1001-5256.2016.07.036
[17]	Liang Shan, Fan ZuoPeng, Nie Wei, Chou LiXia, Chen Jie, Lin Wei, Liu YiRong, Zhang Jing, Hu ZhongJie. Clinical types and features of chronicity of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(12): 2356-2359. doi: 10.3969/j.issn.1001-5256.2016.12.025
[18]	Du ShuiXian, Lu LinLin, Xin YongNing, Liu Yang, Yuan Chen, Gu JiuLian, Xuan ShiYing. Influencing factors for the length of hospital stay in patients with drug-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(7): 1368-1372. doi: 10.3969/j.issn.1001-5256.2016.07.034
[19]	Gan Yu, Dong Yi, Zhang HongFei, Xu ZhiQiang, Chen DaWei, Wang LiMin, Wang FuChuan, Yan JianGuo, Zhu ShiShu. Clinical characteristics and outcomes of drug-induced liver injury in children: a study of 184 cases[J]. Journal of Clinical Hepatology, 2015, 31(8): 1244-1247. doi: 10.3969/j.issn.1001-5256.2015.08.015
[20]	Huang ChunYang, Liu YanMin, Huang YunLi, Han Ying, Zhang XiaoDan, Liao HuiYu. Drug-induced liver injury accompanied by autoimmune phenomena: an analysis of clinical characteristics[J]. Journal of Clinical Hepatology, 2015, 31(8): 1303-1306. doi: 10.3969/j.issn.1001-5256.2015.08.029

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	郭龙鑫，高云娟，吴承钊，龙敏娟，祝胜凯，宋海波，赵旭，肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探. 中国药物警戒. 2024(01): 15-19 .
2.	李勇，张蕾，吴幸福. 老年药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2024(04): 547-550 .
3.	徐媛，方忠宏，冉姗. 1例多因素所致药物性肝损伤病例的病因论证与药学监护. 药物流行病学杂志. 2023(03): 350-355 .
4.	郭冬伟. 生物技术药物的免疫毒性和免疫原性的分析及探讨. 当代化工研究. 2021(03): 161-162 .
5.	李任，苏庆全，黎运. 62例肺结核患者抗结核药物治疗致药物性肝损伤的危险因素分析及其防治对策. 抗感染药学. 2021(05): 724-726 .
6.	杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 .
7.	王巧玲，邹正升. 细胞色素P450基因多态性与药物性肝损伤的关系. 临床肝胆病杂志. 2020(05): 1150-1153 . 本站查看
8.	许维国. 中草药导致药物性肝损伤的现状及研究进展. 中国处方药. 2020(06): 14-16 .
9.	刘毅，周淑娴，陈念辉. 1例药源性肝损伤合并2型糖尿病患者的病例分析. 中国药师. 2020(10): 1986-1989 .
10.	陈龙，李钺. 肝切除术后并发症的危险因素及预测评分系统. 临床肝胆病杂志. 2019(01): 217-221 . 本站查看
11.	郭永涛. 抗肺结核药物所致肝损伤患者临床症状分布及危险因素分析. 山西医药杂志. 2019(05): 564-566 .
12.	刘丽艳，唐晓雯，董春玲，陶茹，刘成海，张雅丽. 药物性肝损伤患者的护理研究进展. 护士进修杂志. 2019(24): 2253-2256 .

Other cited types(8)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2215) PDF downloads(404)

Clinical features of drug-induced liver injury and related risk factors

DOI: 10.3969/j.issn.1001-5256.2018.06.021

Abstract

References

Relative Articles

Cited by

Periodical cited type(12)

Other cited types(8)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content